Here are four companies awaiting regulatory decisions in July, as listed by Zacks.
- Puma Biotechnology seeks FDA approval for neratinib — a follow-up treatment for a form of early stage breast cancer. The drug company expects a response from the FDA by the end of the month.
- Ocular Therapeutix‘s drug Dextenza is a treatment for eye pain following ophthalmic surgery. The company expects a response from the FDA July 19.
- Eagle Pharmaceuticals expects to hear from the FDA on July 23 regarding the review of its external heat stroke treatment Ryanodex.
- Amgen and UCB will learn if their osteoporosis drug Evenity earns FDA approval July 19.
More articles on supply chain:
6 drugmakers in the headlines
10 most-read supply chain stories in June
Teens have limited access to emergency contraception: 4 study findings
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
